Study S000352

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes and Inadequate Glycemic Control Treated With Lifestyle Modification and Oral Antidiabetic Medications

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01029886
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 912
Start: 2010-01
Primary completion: 2011-01
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:exenatide once weekly; DRUG:liraglutide
Results posted: TRUE

Registered primary outcomes

Change in HbA1c From Baseline to Week 26 [Baseline, Week 26]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016299	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Buse JB, Lancet (London, England)	2013	Randomized trial	PMID 23141817 DOI	cites ClinicalTrials.gov:NCT01029886; registry reference DERIVED:23141817
R0019490	Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials. Grimm M, Postgraduate medicine	2013	Randomized trial	PMID 23748506 DOI	cites ClinicalTrials.gov:NCT01029886; registry reference DERIVED:23748506
R0050287	Efficacy and Safety of Once-Weekly Exenatide versus Daily Liraglutide in Subjects with T2DM (DURATION-6) Robert E. Buckley, MD Conference Express	2011	Other trial	DOI	cites ClinicalTrials.gov:NCT01029886